Tomahawk, WI 9/27/2013 (BasicsMedia) – Headquartered in Dublin, the Ireland-based Amarin Corporation plc (ADR) (NASDAQ:AMRN)’s strategic focus remains on development and commercialization of pharmaceutical products for the treatment of cardiovascular diseases.  The company’s market capitalization is around $1.1 billion. Vascepa is the lead and lone marketed product for the Amarin. Despite having kept all its egg in the single basket named Vascepa, the company offers an excellent investment opportunity to potential investors driven by the market potential Vascepa has to offer and the company’s advantageous patent portfolio.

About Vascepa

Vascepa, an omega-3 fish oil therapy and the company’s first and only FDA approved product, is indicated for the treatment in patients with severe hypertriglyceridemia (≥500 mg/dL) to reduce triglyceride levels. During the study trial, it also demonstrated significant decrease in certain other important lipid biomarkers including Total Cholesterol (TC) and Very Low-Density Lipoprotein Cholesterol (VLDL-C). It was launched in the United States’ markets during January 2013 as the prescription drug. The normalized prescriptions for the drug jumped over 4.5 times during 2Q13 (47,300 prescriptions) compared to 1Q13 (10,500 prescriptions). Vascepa has generated sales worth $7.8 million during 1H13, of which, significant sales were generated during 2Q13 totaling around $5.5 million.

The Vascepa Advantage

The Vascepa is also undergoing two more clinical trials named the ANCHOR trial and the REDUCE-IT trial. The ANCHOR trial is indicated for patients with high triglycerides (≥200 mg/dL and <500 mg/dL) for the reduction of triglyceride level. One of the critical secondary endpoint was to assess the lack of elevation in Low-Density Lipoprotein Cholesterol (LDL-C) as such elevation in LDL-C is usually found associated in cholesterol lowering therapy, offsetting the potential outcome. The trial has met both its primary and secondary endpoints with comparable safety profile and no treatment-related serious adverse events reported. As of date, the trial results are under the USFDA review and following the approval this drug is estimated to cater almost ten times larger market.

The REDUCE-IT trial is indicated to evaluate the effectiveness of Vascepa in reducing cardiovascular event among high risk patient population having elevated triglyceride levels (>150 mg/dL) and either coronary heart disease or risk factors for coronary heart disease. The study, to evaluate the effectiveness of Vascepa as an add-on to statin therapy, is planned to recruit approximately 8,000 patients over 400 clinical sites worldwide. Amarin Corporation (NASDAQ:AMRN) recently announced that the study has already enrolled more than 6000 patients. The market size for this indication of Vascepa is estimated to be almost twice that of the already marked product and the ANCHOR trial.

Earlier in September 2013, Amarin Corporation (NASDAQ:AMRN) announced to have 30 patents issued or allowed to its lead product Vascepa by the United States Patent and Trademark Office. In addition the company also has over 30 additional patent applications pending in the United States, allowing it to have the most expanding and extensive patent portfolio.

Potential Threats to Vascepa

Lovaza – another omega-3 fatty acid treatment licensed by GlaxoSmithKline (NYSE: GSK), remains the lead competitor for Vascepa with peak sales of over $1 billion. In addition the generic versions of the Lovaza are also expected to hit the market pretty soon.

Another potential competition could be offered by AstraZeneca (NYSE:AZN)’s yet-to-come product which is planned for a large scale cardiovascular trial. If the new product will do well in the study trials and get the nod of approval, it will directly compete with Vascepa as well as Lovaza for the market share.

DISCLAIMER: This content is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.